Essential fatty acids in plasma phospholipids in schizophrenics

Horrobin, David F.; Manku, M.S.; Morse-Fisher, N.; Vaddadi, Krishna S; Courtney, Paul; Glen, A.I.M.; Glen, E.M.T.; Spellman, Mitchell W.; Bates, C.

doi:10.1016/0006-3223(89)90216-3

Cited by 73 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…47 An increased level of plasma 20:3n9 was not demonstrated either in the present study or other schizophrenic patient groups. 48,49 Lack of increased level 20:3n9 was also found in RBC ghost membranes of patients with chronic schizophrenia on and off antipsychotic treatment. 50 It is thus reasonable …”

Section: Possible Mechanisms Involving Altered Pufas Pathwaysmentioning

confidence: 94%

Metabolomic mapping of atypical antipsychotic effects in schizophrenia

Kaddurah‐Daouk

McEvoy

Baillie³

et al. 2007

Mol Psychiatry

233

181

View full text Add to dashboard Cite

Schizophrenia is associated with impairments in neurotransmitter systems and changes in neuronal membrane phospholipids. Several atypical antipsychotic drugs induce weight gain and hypertriglyceridemia. To date, there has not been a comprehensive evaluation and mapping of global lipid changes in schizophrenia, and upon treatment with antipsychotics. Such mapping could provide novel insights about disease mechanisms and metabolic side effects of therapies used for its treatment. We used a specialized metabolomics platform 'lipidomics' that quantifies over 300 polar and nonpolar lipid metabolites (across seven lipid classes) to evaluate global lipid changes in schizophrenia and upon treatment with three commonly used atypical antipsychotics. Lipid profiles were derived for 50 patients with schizophrenia before and after treatment for 2-3 weeks with olanzapine (n = 20), risperidone (n = 14) or aripiprazole (n = 16). Patients were recruited in two cohorts (study I, n = 27 and study II, n = 23) to permit an internal replication analyses. The change from baseline to post-treatment was then compared among the three drugs. Olanzapine and risperidone affected a much broader range of lipid classes than aripiprazole. Approximately 50 lipids tended to be increased with both risperidone and olanzapine and concentrations of triacylglycerols increased and free fatty acids decreased with both drugs but not with aripiprazole. Phosphatidylethanolamine concentrations that were suppressed in patients with schizophrenia were raised by all three drugs. Drug specific differences were also detected. A principal component analysis (PCA) identified baseline lipid alterations, which correlated with acute treatment response. A more definitive long-term randomized study of these drugs correlating global lipid changes with clinical outcomes could yield biomarkers that define drug-response phenotypes.

show abstract

Section: Possible Mechanisms Involving Altered Pufas Pathwaysmentioning

confidence: 94%

Metabolomic mapping of atypical antipsychotic effects in schizophrenia

Kaddurah‐Daouk

McEvoy

Baillie³

et al. 2007

Mol Psychiatry

233

181

View full text Add to dashboard Cite

show abstract

“…Horrobin et al (45,46) first proposed that relationships could exist between schizophrenia and changes in the status of EFA, showing a tendency toward lower amounts of plasma PUFA, especially linoleic acid. However, further findings concerning the levels of EFA in erythrocytes suggested that two schizophrenic populations could be distinguished, i.e., one with EFA levels similar to those of controls and another with reduced amounts of n-6 and n-3 PUFA, especially AA and DHA (47)(48)(49).…”

Section: Pufa and Cns Disorders: Clinical Datamentioning

confidence: 98%

Polyunsaturated fatty acids and cerebral function: Focus on monoaminergic neurotransmission

Chalon

Vancassel²,

Zimmer

et al. 2001

Lipids

160

View full text Add to dashboard Cite

More and more reports in recent years have shown that the intake of polyunsaturated fatty acids (PUFA) constitutes an environmental factor able to act on the central nervous system (CNS) function. We recently demonstrated that the effects of PUFA on behavior can be mediated through effects on the monoaminergic neurotransmission processes. Supporting this proposal, we showed that chronic dietary deficiency in alpha-linolenic acid in rats induces abnormalities in several parameters of the mesocortical and mesolimbic dopaminergic systems. In both systems, the pool of dopamine stored in presynaptic vesicles is strongly decreased. This may be due to a decrease in the number of vesicles. In addition, several other factors of dopaminergic neurotransmission are modified according to the system affected. The mesocortical system seems to be hypofunctional overall [e.g., decreased basal release of dopamine (DA) and reduced levels of dopamine D2 (DAD2) receptors]. In contrast, the mesolimbic system seems to be hyperfunctional overall (e.g., increased basal release of DA and increased levels of DAD2 receptors). These neurochemical changes are in agreement with modifications of behavior already described with this deficiency. The precise mechanisms explaining the effects of PUFA on neurotransmission remain to be clarified. For example, modifications of physical properties of the neuronal membrane, effects on proteins (receptors, transporters) enclosed in the membrane, and effects on gene expression and/or transcription might occur. Whatever the mechanism, it is therefore assumed that interactions exist among PUFA, neurotransmission, and behavior. This might be related to clinical findings. Indeed, deficits in the peripheral amounts of PUFA have been described in subjects suffering from neurological and psychiatric disorders. Involvement of the monoaminergic neurotransmission function has been demonstrated or hypothesized in several of these diseases. It can therefore be proposed that functional links exist among PUFA status, neurotransmission processes, and behavioral disorders in humans. Animal models are tools of choice for the understanding of such links. Improved prevention and complementary treatment of neurological and psychiatric diseases can be expected from these studies.

show abstract

“…Ten studies show decreased levels of n-3PUFA in schizophrenics compared with controls, while four studies show elevated levels of n-3PUFA in schizophrenics compared with controls (83,189,190 -198) . Two studies show increases in n-6PUFA:n-3PUFA (arachidonic acid: DHA) ratios in schizophrenics compared with controls (91,201) and two studies show decreases in n-6PUFA:n-3PUFA ratios (190,198) . All studies except five (91,189,195 -197) also found decreased n-6PUFA in schizophrenics compared with controls.…”

Section: Clinical Evidencementioning

confidence: 99%

Is there a role forn-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials

2008

View full text Add to dashboard Cite

Selected biochemical evidence suggests a potential role for n-3 long-chain PUFA (n-3PUFA) in the regulation of mood and behaviour. The present paper reviews the relevant evidence, to date, from epidemiological studies, clinical studies and intervention trials. Most evidence is available investigating a role for n-3PUFA in depression, depressive illness and suicidal behaviour, but work is also available on anxiety and anxiety-related disorders, fatigue and fatigue-related disorders, aggression, hostility and anti-social behaviour, inattention, impulsivity and attention deficit hyperactivity disorder and schizophrenic disorders. For all these aspects of mood and behaviour, the evidence available is currently limited and highly inconsistent, both in terms of study methodology and study findings. There is a clear need for further work in this area.

show abstract

Essential fatty acids in plasma phospholipids in schizophrenics

Cited by 73 publications

References 18 publications

Metabolomic mapping of atypical antipsychotic effects in schizophrenia

Metabolomic mapping of atypical antipsychotic effects in schizophrenia

Polyunsaturated fatty acids and cerebral function: Focus on monoaminergic neurotransmission

Is there a role forn-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials

Contact Info

Product

Resources

About